GPCRs have the most potential target for a variety of drug discovery projects, ranging from blood pressure management, diabetes, genetic disorder treatment and cancer treatment, has arisen. Activation of these receptors is the responsibility of a panel of diverse ligands, including hormones, peptides, ions and small molecules. Main GPCRs, whose mutations or altered expressions are associated with tumorgenicity, have been identified by molecular genetics. In this study, we addressed recent developments in the participation of GPCRs in cancer progression and approaches to controlling the process underlying GPCRs involving tumor growth and metastasis in the treatment of various forms of human cancer.

While the human genome contains over 350 non-olfactory G-protein coupled receptors (GPCRs), only 135 are targeted by currently approved medicines. Among these 135 targets, and even more among the remaining >200 GPCRs, including 120 orphans, various biopharmaceutical companies claim that there are substantial untapped resources that have not been successfully pursued to date. The largest and most diverse GPCR family, the Rhodopsin family, is currently characterized by the largest number of both known and investigational targets, with therapeutic agents targeting more than 150 GPCRs. The other GPCR families are also distinguished by substantial therapeutic ability, with 34 and 21 separate drugs targeting at least 14 of the 15 members of the Secretin family and 11 of the 22 members of the Glutamate family, respectively.

Adroit Market Research study on the global market for G-protein coupled receptors offers a holistic view of the industry from 2020 to 2028 as forecast period, including factors such as market drivers, limitations, opportunities, threats and regulatory overview. The market has been analyzed from 2018 to 2028, with a base year estimate of 2019 and a projection from 2020 to 2028. The report covers the current status and potential characteristics of the market at both the global and the country level. Moreover, the report also assesses market competition with Porter's analysis of five strengths and places leading players on the basis of their product range, regional presence, strategic initiatives and overall sales. Prominent players in the global composite resin market have been analyzed in depth.

In terms of product, cell lines accounted for dominant market share owing to availability of wide portfolio. In the cellular impedance assays for the identification of GPCR targets, cell lines play a major role, thereby attributing to the expected revenue share. In recent years, detection kits have gained prominence as they are an easy-to-use, durable, and highly responsive product for analysing behaviour across various pathways. In addition, new detection techniques focused on non-label systems, such as resonance wave-guide grating or impedance-based sensors, are expected to help segment expansion.

North America is predicted to lead the global market and is expected to preserve its position over the forecast period. Factors such as strategic investments in cancer research, approvals of GPCR-targeted medicines, and expanded focus on drug discovery & growth activities are key reasons for regional market dominance. 134 GPCR drug targets were accepted in the U.S. or European Union in November 2017 and 128 targets were reported in the orange FDA book.

The key players of global market report include,  Abcam PLC, Becton, Dickinson and Company, PerkinElmer Inc.,  Merck KGaA, Enzo Biochem Inc., Danaher Corporation, Promega Corporation, Bioinvenu Corporation, Thermo Fisher Scientific Inc, and many more.

Key Segments of the Global G-protein coupled receptors Market

Product Overview, 2018-2028 (USD Million)

• Cell Lines
• Detection Kits
• Cell Culture Reagents
• Ligands

Assay Type Overview, 2018-2028 (USD Million)

•  cAMP Functional Assays
• Calcium Functional Assays
• β-Arrestin Functional Assays
• Radioligand Binding and GTPγS Functional Assays
• Internalization Assays
• Trafficking Assays
• Other Assays

Application Overview, 2018-2028 (USD Million)

• Cancer Research
• CNS Research
• Metabolic Research
• Cardiovascular Research
• Inflammation Research
• Respiratory Research
• Other Applications

Regional Overview, 2018-2028 (USD Million)

• North America
  • U.S.
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia-Pacific
• Middle East and Africa
  • UAE
  • South Africa
  • Rest of Middle East and Africa
• South America
  • Brazil
  • Rest of South America